A comparative clinical study investigating the efficacy of a test dentifrice containing 8% strontium acetate and 1040 ppm sodium fluoride versus a marketed control dentifrice containing 8% arginine, calcium carbonate, and 1450 ppm sodium monofluorophosphate in reducing dentinal hypersensitivity
- PMID: 20669816
A comparative clinical study investigating the efficacy of a test dentifrice containing 8% strontium acetate and 1040 ppm sodium fluoride versus a marketed control dentifrice containing 8% arginine, calcium carbonate, and 1450 ppm sodium monofluorophosphate in reducing dentinal hypersensitivity
Abstract
Objective: The objective of this clinical study was to evaluate and compare the efficacy in reducing dentin hypersensitivity of an 8% strontium acetate, 1040 ppm sodium fluoride dentifrice to a marketed control 8% arginine, calcium carbonate, 1450 ppm sodium monofluorophosphate dentifrice after twice-daily brushing for two, four, and eight weeks.
Methods: This was a randomized, examiner-blind, two-arm parallel group, eight-week longitudinal clinical study with seventy-nine subjects, stratified based on baseline tooth sensitivity (Schiff score, Yeaple). Subjects brushed with either an 8% strontium acetate-based dentifrice or a marketed 8% arginine calcium carbonate dentifrice twice daily for approximately one minute. At screening, baseline, weeks two, four, and eight, subjects' tooth sensitivity was determined through both evaporative (Schiff and Visual Analogue Scale [VAS]) and tactile stimuli (Yeaple probe). Subject assessments using each stimulus were performed by the same examiner throughout the study.
Results: Seventy-seven subjects completed this clinical study. Both subject groups exhibited significant cumulative reductions from baseline to Days 14, 28, and 56 in dentin hypersensitivity as measured by Schiff, Yeaple, and VAS (for the 8% strontium acetate group, p < or = 0.0001 for all time points; for the 8% arginine calcium carbonate group, p = 0.0031 for Yeaple at Day 14, p = 0.0015 for VAS at Day 14, and p < 0.0001 for all remaining measures and time points). No significant differences (p > 0.05) were observed between treatments for any of the time points and measures except for tactile sensitivity at Day 56, for which the 8% strontium acetate-based dentifrice was statistically superior (p = 0.0391) to the control 8% arginine calcium carbonate dentifrice.
Conclusion: The 8% strontium acetate, 1040 ppm sodium fluoride dentifrice provided significant reductions in dentin hypersensitivity (p < 0.0001) after two, four, and eight weeks of product use. Comparisons to a control 8% arginine calcium carbonate dentifrice showed no significant differences (p > 0.05) apart from tactile (Yeaple) sensitivity at week 8, where the 8% strontium acetate-based dentifrice showed significant improvement over the control (p = 0.0391).
Similar articles
-
Clinical efficacy in reducing dentin hypersensitivity of a dentifrice containing 8.0% arginine, calcium carbonate, and 1450 ppm fluoride compared to a dentifrice containing 8% strontium acetate and 1040 ppm fluoride under consumer usage conditions before and after switch-over.J Clin Dent. 2011;22(4):128-38. J Clin Dent. 2011. PMID: 22403989 Clinical Trial.
-
A comparative clinical study investigating the efficacy of a dentifrice containing 8% strontium acetate and 1040 ppm fluoride in a silica base and a control dentifrice containing 1450 ppm fluoride in a silica base to provide immediate relief of dentin hypersensitivity.J Clin Dent. 2010;21(2):42-8. J Clin Dent. 2010. PMID: 20669815 Clinical Trial.
-
Comparing the efficacy in providing instant relief of dentin hypersensitivity of a new toothpaste containing 8.0% arginine, calcium carbonate, and 1450 ppm fluoride to a benchmark desensitizing toothpaste containing 2% potassium ion and 1450 ppm fluoride, and to a control toothpaste with 1450 ppm fluoride: a three-day clinical study in Mississauga, Canada.J Clin Dent. 2009;20(4):115-22. J Clin Dent. 2009. PMID: 19831164 Clinical Trial.
-
The efficacy of a new dentifrice containing 8.0% arginine, calcium carbonate, and 1450 ppm fluoride in delivering instant and lasting relief of dentin hypersensitivity.J Clin Dent. 2009;20(4):109-14. J Clin Dent. 2009. PMID: 19831163 Review. No abstract available.
-
Recent advances in dentin hypersensitivity: clinically proven treatments for instant and lasting sensitivity relief.Am J Dent. 2010 May;23 Spec No A:3A-13A. Am J Dent. 2010. PMID: 21284246 Review.
Cited by
-
In situ randomised trial to investigate the occluding properties of two desensitising toothpastes on dentine after subsequent acid challenge.Clin Oral Investig. 2013 Jan;17(1):195-203. doi: 10.1007/s00784-012-0683-7. Clin Oral Investig. 2013. PMID: 22315153 Clinical Trial.
-
Reducing dentine hypersensitivity with nano-hydroxyapatite toothpaste: a double-blind randomized controlled trial.Clin Oral Investig. 2018 Jan;22(1):313-320. doi: 10.1007/s00784-017-2113-3. Epub 2017 Mar 30. Clin Oral Investig. 2018. PMID: 28361171 Clinical Trial.
-
Strontium Carbonate and Strontium-Substituted Calcium Carbonate Nanoparticles Form Protective Deposits on Dentin Surface and Enhance Human Dental Pulp Stem Cells Mineralization.J Funct Biomater. 2022 Nov 17;13(4):250. doi: 10.3390/jfb13040250. J Funct Biomater. 2022. PMID: 36412891 Free PMC article.
-
Randomised clinical studies investigating immediate and short-term efficacy of an occluding toothpaste in providing dentine hypersensitivity relief.BMC Oral Health. 2019 Jun 4;19(1):98. doi: 10.1186/s12903-019-0781-x. BMC Oral Health. 2019. PMID: 31164116 Free PMC article. Clinical Trial.
-
Twelve-Month Follow-Up of Different Dentinal Hypersensitivity Treatments by Photobiomodulation Therapy, Nd:YAG and Nd:YAP Lasers.Life (Basel). 2022 Nov 30;12(12):1996. doi: 10.3390/life12121996. Life (Basel). 2022. PMID: 36556361 Free PMC article.